DexCom, Inc.
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems for the management of diabetes and metabolic health in the United States and internationally. The company offers Dexcom G7 and G7 15 Day, an integrated con…
What to know about DXCM
DexCom, Inc. is a large Healthcare company with a mixed financial profile. It scores well on growth and health, but risk is worth keeping an eye on.
Should you consider DXCM?
Based on 31 financial metrics and sector comparison. Not financial advice.
-
DexCom, Inc. is a large-cap Healthcare company with a mixed overall financial profile — it sits in the upper half of Healthcare stocks (22 of 59).
-
The business is both profitable and financially healthy — it keeps a good portion of what it earns and carries its debt comfortably.
-
The stock trades at a premium — investors are paying more per dollar of earnings than most S&P 500 companies. That's fine if strong growth justifies it, but leaves little room for disappointment.
-
Growth is a clear strength — revenue and earnings are expanding faster than most peers, signalling strong demand for the company's products or services.
-
This stock pays no dividend — your return depends entirely on the share price rising over time.
-
The stock is more volatile than most S&P 500 names — it can swing sharply in both directions. This suits investors comfortable with bigger short-term moves.
-
There are several areas of concern. This may suit investors with a higher risk tolerance or a specific contrarian view on the Healthcare sector.
At a glance
How it scores
We look at 31 different financial metrics and group them into categories. Here's how DXCM compares to the other S&P 500 stocks.
Dive deeper — all 31 metrics 9 categories · valuation, growth, health, dividends & more Show all Hide
Valuation
Is the stock cheap or expensive relative to its earnings, sales, and assets? Lower multiples often mean better value.
| Metric | Value | vs S&P 500 |
|---|---|---|
| P/E Ratio (Trailing) | 31.10 | Average |
| Forward P/E | 23.51 | Average |
| PEG Ratio | 1.36 | Above avg |
| Price to Sales | 5.80 | Average |
| Price to Book | 9.46 | Below avg |
| EV/EBITDA | 21.05 | Average |
| Earnings Yield | 3.22% | Average |
Profitability
How efficiently does the company turn revenue into profit? Higher margins mean more money kept from each dollar earned.
| Metric | Value | vs S&P 500 |
|---|---|---|
| Gross Margin | 61.50% | Top 25% |
| Operating Margin | 21.42% | Above avg |
| Net Profit Margin | 19.31% | Above avg |
| Return on Equity | 35.62% | Top 25% |
| Return on Invested Capital | 9.65% | Top 25% |
Growth
How fast is the business expanding? Strong growth in revenue and earnings signals increasing market demand.
| Metric | Value | vs S&P 500 |
|---|---|---|
| Revenue Growth (YoY) | 15.00% | Above avg |
| Revenue Growth (3Y CAGR) | 17.01% | Top 25% |
| EPS Growth (YoY) | 92.20% | Top 25% |
| Free Cash Flow Growth | 70.79% | Top 25% |
Health
Can the company cover its debts and obligations? A healthy balance sheet reduces the risk of financial trouble.
| Metric | Value | vs S&P 500 |
|---|---|---|
| Current Ratio | 1.95 | Top 25% |
| Debt to Equity | 0.47 | Top 25% |
| Interest Coverage | 60.48 | Top 25% |
| Altman Z-Score | 6.88 | Top 25% |
Dividends
Does the company pay shareholders, and is that payment growing and sustainable?
| Metric | Value | vs S&P 500 |
|---|---|---|
| Dividend Yield | — | N/A |
| Payout Ratio | — | N/A |
| Dividend Growth (5Y) | — | N/A |
Cash Flow
Is real cash flowing into the business — not just accounting profits? Strong cash flow funds growth and dividends.
| Metric | Value | vs S&P 500 |
|---|---|---|
| Free Cash Flow Yield | 5.11% | Above avg |
| OCF to Sales | 37.00% | Top 25% |
Risk
How volatile is the stock compared to the broader market? Lower beta and volatility mean a smoother ride.
| Metric | Value | vs S&P 500 |
|---|---|---|
| Beta (1-Year) | 1.44 | Below avg |
| Volatility (30-Day) | 45.69% | Below avg |
Sentiment
What do analysts and short-sellers think? High analyst ratings and low short interest signal broad confidence.
| Metric | Value | vs S&P 500 |
|---|---|---|
| Short % of Float | 5.19% | Average |
| Avg. Analyst Rating | 1.33 | Top 25% |
| Target Upside % | 17.58% | Above avg |
Size
How large is the company by market value? Size affects stability, growth potential, and index inclusion.
| Metric | Value | vs S&P 500 |
|---|---|---|
| Market Capitalization | 27.96B | Average |
How does DXCM compare to…?
Pick another stock and see them side by side in seconds.
You might also look at
Companies in a similar position to DXCM — based on their financial profile.